Join to view full profile
1920 Colorado AveSanta Monica, CA 90404
Phone+1 310-319-4700
Fax+1 310-301-8751
Dr. Relan is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Family Medicine, 1999 - 2002
David Geffen School of Medicine at UCLAClass of 1999
University of California, Los AngelesMPH, Health Services, 1997 - 1998
University of California, BerkeleyBA, Economics, 1990 - 1994
Certifications & Licensure
CA State Medical License 2001 - 2028
American Board of Family Medicine Family Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
Clinical Trials
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
Publications & Presentations
PubMed
- 26 citationsInterim analysis: Open-label extension study of leniolisib for patients with APDS.V Koneti Rao, Elaine Kulm, Anna Šedivá, Alessandro Plebani, Catharina Schuetz
The Journal of Allergy and Clinical Immunology. 2024-01-01 - 82 citationsA randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.V Koneti Rao, Sharon Webster, Anna Šedivá, Alessandro Plebani, Catharina Schuetz
Blood. 2023-03-02 - 6 citationsRecombinant human C1 esterase inhibitor for hereditary angioedema attacks: A European registryAnna Valerieva, Maria Staevska, Vesna Grivcheva-Panovska, Milos Jesenak, Kinga Viktória Kőhalmi
The World Allergy Organization Journal. 2021-04-01
Journal Articles
- A Review of Hereditary Angioedema and Recombinant Human C1-Inhibitor TreatmentBork K, Triggiani M, Caballero T, Relan A, European Gastroenterology and Hepatology Review
Press Mentions
Pharming Appoints Anurag Relan as Chief Medical Officer and Robert Friesen as Chief Scientific OfficerJune 17th, 2021- Pharming Announces First Patient Enrolled in Phase III Clinical Trial of Leniolisib for the Treatment of APDS in JapanAugust 10th, 2023
Industry Relationships
- Medical Director, Pharming2007 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
